Literature DB >> 8387613

Characterization of X-linked adrenoleukodystrophy in different biological specimens from ten Portuguese families.

P Jorge1, D Quelhas, A Nogueira.   

Abstract

X-linked adrenoleukodystrophy (ALD) is a severe neurodegenerative disease characterized by progressive demyelination, adrenocortical insufficiency and accumulation in tissues and body fluids of unbranched, saturated very long-chain fatty acids (VLCFA). The diagnosis of ALD is usually based on clinical history, neurological examination and the determination of levels of VLCFA in plasma and cultured skin fibroblasts. In the present paper we report the biochemical findings in plasma, cultured skin fibroblasts and lymphoblastoid cell lines from ALD patients. The results obtained indicate that the increment of the ratios C24:0 to C22:0 and C26:0 to C22:0 and of the concentration C26:0 (micrograms/ml) in plasma was parallel with that of fibroblasts, but not with that of Epstein-Barr virus (EBV)-transformed lymphocytes, suggesting that this cell line is not reliable for diagnosis of ALD by VLCFA analysis. Subsequent studies carried out on family members revealed heterozygotes other than obligate carriers and hemizygotes who were pre-symptomatic or had a misdiagnosis of multiple sclerosis or psychosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8387613     DOI: 10.1007/bf00711315

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  15 in total

1.  A human skin culture technique used for cytological examinations.

Authors:  D G HARNDEN
Journal:  Br J Exp Pathol       Date:  1960-02

2.  The efficacy of very long-chain fatty acid analysis in the diagnosis of peroxisomal disorders: an audit report.

Authors:  R A Harkness; G W Lynes; A W Johnson
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

Review 3.  The inborn errors of peroxisomal beta-oxidation: a review.

Authors:  R J Wanders; C W van Roermund; R B Schutgens; P G Barth; H S Heymans; H van den Bosch; J M Tager
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

4.  A comparison of erythrocytes, lymphocytes and blood plasma as samples in fatty acid analysis for the diagnosis of adrenoleukodystrophy.

Authors:  Y Antoku; Y Ohtsuka; H Nagara; T Sakai; K Tsukamoto; H Iwashita; I Goto
Journal:  J Neurol Sci       Date:  1989-12       Impact factor: 3.181

Review 5.  Adrenoleukodystrophy: biochemical procedures in diagnosis, prevention and treatment.

Authors:  P A Watkins; S Naidu; H W Moser
Journal:  J Inherit Metab Dis       Date:  1987       Impact factor: 4.982

6.  Adrenoleukodystrophy: elevated C26 fatty acid in cultured skin fibroblasts.

Authors:  H W Moser; A B Moser; N Kawamura; J Murphy; K Suzuki; H Schaumburg; Y Kishimoto
Journal:  Ann Neurol       Date:  1980-06       Impact factor: 10.422

7.  Conclusive evidence that very-long-chain fatty acids are oxidized exclusively in peroxisomes in human skin fibroblasts.

Authors:  B S Jakobs; R J Wanders
Journal:  Biochem Biophys Res Commun       Date:  1991-08-15       Impact factor: 3.575

8.  Identification of female carriers of adrenoleukodystrophy.

Authors:  H W Moser; A E Moser; J E Trojak; S W Supplee
Journal:  J Pediatr       Date:  1983-07       Impact factor: 4.406

9.  Adrenoleukodystrophy: survey of 303 cases: biochemistry, diagnosis, and therapy.

Authors:  H W Moser; A E Moser; I Singh; B P O'Neill
Journal:  Ann Neurol       Date:  1984-12       Impact factor: 10.422

10.  Adrenoleukodystrophy: increased plasma content of saturated very long chain fatty acids.

Authors:  H W Moser; A B Moser; K K Frayer; W Chen; J D Schulman; B P O'Neill; Y Kishimoto
Journal:  Neurology       Date:  1981-10       Impact factor: 9.910

View more
  1 in total

1.  X-linked adrenoleukodystrophy in patients with idiopathic Addison disease.

Authors:  P Jorge; D Quelhas; P Oliveira; R Pinto; A Nogueira
Journal:  Eur J Pediatr       Date:  1994-08       Impact factor: 3.183

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.